Navigation Links
JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism

JMAR Technologies, Inc. (OTCBB: JMAR), San Diego, CA, a leading innovator in the development and commercialization of sensing systems for the detection of chemical, biological, radiological, nuclear and explosive (CBRNE) materials, today announced a media awareness initiative for JMAR's award-winning, laser-based BioSentry®, which is the only commercialized, EPA tested, online system for real-time detection of pathogens in water.

San Diego, CA (PRWEB) January 13, 2009 -- U.S. water distribution systems are potential terrorist targets due to the critical need for clean water in all sectors of society. A terrorist attack that contaminates a public or private municipal water system will cause devastating economic and public health consequences. With the most recent warnings of bio-attack threats, JMAR is alerting the public, our government officials, and the incoming Obama Administration about the benefits of using BioSentry®. As a high tech counter to bioterrorism, BioSentry® can help prevent economic and political disruption, widespread sickness, and fatalities from contaminated water that goes undetected until it is too late.

As part of this initiative, JMAR representatives are attending a conference in Washington, D.C., which specifically addresses "Shaping the Obama Administration's Counterterrorism Strategy," at the CATO Institute on January 12-13, 2009. Later this week, on January 15, 2009, CNBC will be airing a prime-time BioSentry® video news release. The video is expected to reach 4,000,000 viewers, and will also be distributed to 190 cable stations nationwide through the Independent News Network.

"I have the utmost confidence that this initiative will be successful in highlighting the nature of the threat and the importance of taking action now to protect the public from a bioterrorist attack, " said JMAR's Chief Executive Officer, C. Neil Beer, Ph.D. "We need to secure our water supplies - BioSentry® provides the continuous monitoring necessary for protection against contamination, intentional or otherwise."

Frost & Sullivan recognized BioSentry® as the leading innovative approach to water quality monitoring and selected JMAR for their 2008 Biological Detection Product of the Year Award.

To be added to JMAR Technologies' investor lists, please contact Haris Tajyar at 818-382-9702.

About JMAR:
JMAR Technologies, Inc. (OTCBB: JMAR) is a leading innovator in the development and commercialization of sensing systems for the detection of chemical, biological, radiological, nuclear and explosive (CBRNE) materials. Coupled with its established expertise in building advanced laser systems, JMAR provides solutions for a broad range of military, industrial and commercial applications. The Company draws on more than twenty years of experience and twenty-nine patents and patents pending in photonics, laser and detection technologies to develop products and solutions that address some of the world's most pressing issues such as water quality, hazard detection and homeland security. JMAR's vision is to continue to develop innovative technologies and products that support the advancement of global health, safety, and security initiatives. For further information on JMAR Technologies, please visit JMAR Technologies Website.

About CATO:
The Cato Institute was founded in 1977 by Edward H. Crane. It is a non-profit public policy research foundation headquartered in Washington, D.C. Its mission is to increase the understanding of public policies based on the principles of limited government, free markets, individual liberty and speech.

Forward Looking Statements: This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the uncertainty of acceptance in the market for our products and technologies or the acceptance of our customers' products or technologies which incorporate our products and technologies, the failure of our technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR's products, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2007 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
Related Image:
JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association ... 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award ... work with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
Breaking Biology News(10 mins):